Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
1.010
-0.010 (-0.98%)
Dec 20, 2024, 4:00 PM EST - Market closed
Cue Biopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2015 |
| Cash & Equivalents | 32.42 | 48.51 | 51.61 | 64.37 | 74.87 | 44.29 | Upgrade
|
| Short-Term Investments | - | - | 24.68 | - | 10 | 15.12 | Upgrade
|
| Cash & Short-Term Investments | 32.42 | 48.51 | 76.29 | 64.37 | 84.87 | 59.41 | Upgrade
|
| Cash Growth | -40.72% | -36.41% | 18.51% | -24.15% | 42.85% | 51.51% | Upgrade
|
| Receivables | 3.15 | 1.7 | 0.06 | 3.14 | 1.42 | 0.75 | Upgrade
|
| Prepaid Expenses | 1.68 | 1.24 | 0.84 | 0.87 | 1.24 | 0.86 | Upgrade
|
| Other Current Assets | - | - | - | 0.08 | - | - | Upgrade
|
| Total Current Assets | 37.26 | 51.45 | 77.19 | 68.47 | 87.53 | 61.02 | Upgrade
|
| Property, Plant & Equipment | 4.6 | 7.12 | 10.7 | 11.92 | 8.88 | 7.18 | Upgrade
|
| Other Intangible Assets | - | - | - | - | - | 0.01 | Upgrade
|
| Other Long-Term Assets | 2.95 | 2.96 | 3.39 | 3.01 | 3.12 | 3.38 | Upgrade
|
| Total Assets | 44.81 | 61.53 | 91.28 | 83.4 | 99.53 | 71.61 | Upgrade
|
| Accounts Payable | 6.47 | 3.5 | 2.73 | 2.59 | 2.07 | 0.88 | Upgrade
|
| Accrued Expenses | 3.2 | 4.14 | 3.55 | 4.62 | 2.79 | 2.23 | Upgrade
|
| Current Portion of Long-Term Debt | 3.96 | 3.96 | 1.96 | - | - | - | Upgrade
|
| Current Portion of Leases | 2.9 | 3.37 | 3.3 | 4.93 | 4.78 | 4.45 | Upgrade
|
| Current Unearned Revenue | 0.26 | 2.11 | - | 0.65 | 6.68 | 4.1 | Upgrade
|
| Other Current Liabilities | - | - | - | 0 | - | - | Upgrade
|
| Total Current Liabilities | 16.79 | 17.08 | 11.55 | 12.79 | 16.32 | 11.66 | Upgrade
|
| Long-Term Debt | 1.33 | 4.2 | 8.04 | - | - | - | Upgrade
|
| Long-Term Leases | 1.33 | 3.16 | 6.02 | 5.12 | 2.37 | 1.35 | Upgrade
|
| Long-Term Unearned Revenue | - | - | - | - | 1.94 | 4.02 | Upgrade
|
| Total Liabilities | 19.44 | 24.45 | 25.6 | 17.91 | 20.62 | 17.02 | Upgrade
|
| Common Stock | 0.06 | 0.05 | 0.04 | 0.03 | 0.03 | 0.03 | Upgrade
|
| Additional Paid-In Capital | 357.67 | 338.23 | 316.19 | 262.91 | 232.16 | 163.07 | Upgrade
|
| Retained Earnings | -332.37 | -301.19 | -250.46 | -197.45 | -153.29 | -108.5 | Upgrade
|
| Comprehensive Income & Other | - | - | -0.1 | - | 0.01 | -0.01 | Upgrade
|
| Shareholders' Equity | 25.37 | 37.09 | 65.68 | 65.49 | 78.91 | 54.58 | Upgrade
|
| Total Liabilities & Equity | 44.81 | 61.53 | 91.28 | 83.4 | 99.53 | 71.61 | Upgrade
|
| Total Debt | 9.51 | 14.7 | 19.32 | 10.05 | 7.15 | 5.8 | Upgrade
|
| Net Cash (Debt) | 22.91 | 33.82 | 56.97 | 54.32 | 77.72 | 53.61 | Upgrade
|
| Net Cash Growth | -40.21% | -40.64% | 4.89% | -30.11% | 44.97% | 36.73% | Upgrade
|
| Net Cash Per Share | 0.46 | 0.74 | 1.60 | 1.74 | 2.71 | 2.43 | Upgrade
|
| Filing Date Shares Outstanding | 63.35 | 48.64 | 43.17 | 33.01 | 30.46 | 26.58 | Upgrade
|
| Total Common Shares Outstanding | 60.21 | 47.22 | 43.04 | 32.2 | 30.35 | 26.56 | Upgrade
|
| Working Capital | 20.47 | 34.37 | 65.64 | 55.68 | 71.21 | 49.37 | Upgrade
|
| Book Value Per Share | 0.42 | 0.79 | 1.53 | 2.03 | 2.60 | 2.05 | Upgrade
|
| Tangible Book Value | 25.37 | 37.09 | 65.68 | 65.49 | 78.91 | 54.57 | Upgrade
|
| Tangible Book Value Per Share | 0.42 | 0.79 | 1.53 | 2.03 | 2.60 | 2.05 | Upgrade
|
| Machinery | 4.35 | 4.29 | 5.62 | 5.55 | 4.51 | 3.87 | Upgrade
|
| Construction In Progress | - | - | - | - | 0.41 | - | Upgrade
|
| Leasehold Improvements | 0.12 | 0.12 | 0.12 | 0.01 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.